Leptin Involvement in Primary Brain and Pituitary Tumors: Therapeutic Potential, Prognostic Value, and Proposed Diagnostic Application

Abstract Objective: The clinical utility and prognostic value of WHO 2017 lineage-based classification of pituitary tumors have not been assessed. This study aimed to (1) To determine the clinical utility of transcription factor analysis for classification of pituitary tumors and (2) To determine the prognostic value of improved lineage-based classification of pituitary tumors. Methods: This was a retrospective evaluation of patients who underwent surgical resection of pituitary tumors at a tertiary referral centre between 1990 and 2016. Included patients were at least 18 years of age and had complete histopathological data, forming the “histological cohort”. Patients with at least 12 months of post-surgical follow up were included in the subgroup “clinical cohort”. The diagnostic efficacy of transcription factor immunohistochemistry in conjunction with hormone immunohistochemistry was compared with hormone immunohistochemistry alone. The prognostic value of identifying “higher risk” histological subtypes was assessed. Results: There were 172 patient tumor samples analyzed in the histological cohort. Of these, there were 96 patients forming the clinical cohort. Subtype diagnosis was changed in 24/172 (14%) of tumors. Within the clinical cohort, there were 21/96 (22%) patients identified with higher risk histological subtype tumors. These were associated with tumor invasiveness (p=0.032), early recurrence (12-24 months, p=0.016), shorter median time to recurrence (38 [IQR 20-68.5] v 15 [IQR 12-27.25] months, p=0.02) and reduced recurrence-free survival (p=0.023). Conclusions: Application of transcription factor analysis, in addition to hormone IHC, is associated with improved diagnostic information.

Download Full-text

Can antioxidant nutraceuticals benefit the menopause?

Menopause International ◽

10.1258/136218002100321785 ◽

2002 ◽

Vol 8 (3) ◽

pp. 98-101

Author(s):

Erick Valencia ◽

Angela Marin ◽

Gil Hardy

Keyword(s):

Breast Cancer ◽

Chronic Diseases ◽

Prognostic Value ◽

Literature Search ◽

Therapeutic Potential ◽

Nutritional Supplements ◽

Ageing Population ◽

Physiological Changes ◽

Menopausal Women

The antioxidants glutathione, selenium and vitamins C and E meet the criteria for nutraceuticals and their in vivo concentrations can undoubtedly influence and improve many disease processes. In an attempt to quantify and correlate their individual roles as nutritional supplements with their therapeutic potential to improve symptoms and lifestyle during the menopause, we conducted a literature search covering the 15 years up to 2001. Few publications were found dealing specifically with menopausal women. Approximately 90% reported research with vitamins and/or selenium and only one paper investigated a possible correlation between glutathione and breast cancer. This relatively low level of research interest in nutritional or antioxidant aspects of the menopause may just reflect a preoccupation with the more general chronic diseases of an ageing population, without necessarily acknowledging the important physiological changes that occur in women. The little encouraging data in the literature should stimulate more research into the prognostic value, mechanisms and efficacy of nutraceutical supplementation that specifically relate to menopausal women.

Download Full-text

Severe respiratory insufficiency during pandemic H1N1 infection: prognostic value and therapeutic potential of pulmonary surfactant protein A

Critical Care ◽

10.1186/s13054-014-0479-z ◽

2014 ◽

Vol 18 (4) ◽

Cited By ~ 2

Author(s):

Monica Fern Tolosa ◽

Nades Palaniyar

Keyword(s):

Respiratory Insufficiency ◽

Pulmonary Surfactant ◽

Prognostic Value ◽

Therapeutic Potential ◽

Protein A ◽

Surfactant Protein ◽

Surfactant Protein A ◽

Pandemic H1n1 ◽

H1n1 Infection ◽

Pulmonary Surfactant Protein

Download Full-text

Prognostic and Therapeutic Value of Apolipoprotein A and a New Risk Scoring System Based on Apolipoprotein A and Adenosine Deaminase in Chronic Lymphocytic Leukemia

Frontiers in Oncology ◽

10.3389/fonc.2021.698572 ◽

2021 ◽

Vol 11 ◽

Author(s):

Xiaoya Yun ◽

Xiang Sun ◽

Xinting Hu ◽

Huimin Zhang ◽

Zixun Yin ◽

...

Keyword(s):

Chronic Lymphocytic Leukemia ◽

Adenosine Deaminase ◽

Scoring System ◽

Prognostic Value ◽

Therapeutic Potential ◽

Lymphocytic Leukemia ◽

Major Protein ◽

Apolipoprotein A ◽

Risk Scoring ◽

Risk Scoring System

Lipid metabolism is related to lymphomagenesis, and is a novel therapeutic target in some hematologic tumors. Apolipoprotein A (ApoA), the major protein of high-density lipoprotein (HDL), plays a crucial role in lipid transportation and protecting against cardiovascular disease, and takes effect on anti-inflammation and anti-oxidation. It is correlated with the prognosis of some solid tumors. Yet, there is no investigation involving the role of ApoA plays in chronic lymphocytic leukemia (CLL). Our retrospective study focuses on the prognostic value of ApoA in CLL and its therapeutic potential for CLL patients. Herein, ApoA is a favorable independent prognostic factor for both overall survival (OS) and progression-free survival (PFS) of CLL patients. ApoA is negatively associated with β2-microglobulin (β2-MG) and advanced stage, which are poor prognostic factors in CLL. Age, Rai stage, ApoA, and adenosine deaminase (ADA) are included in a new risk scoring system named ARAA-score. It is capable of assessing OS and PFS of CLL patients. Furthermore, cell proliferation assays show that the ApoA-I mimetic L-4F can inhibit the proliferation of CLL cell lines and primary cells. In conclusion, ApoA is of prognostic value in CLL, and is a potential therapy for CLL patients. The ARAA-score may optimize the risk stratification of CLL patients.

Download Full-text

Exploring the prognostic value of SCARF1 in non-small cell lung cancers

10.1101/2021.01.28.428617 ◽

2021 ◽

Author(s):

Daniel A. Patten ◽

Shishir Shetty

Keyword(s):

Endothelial Cells ◽

Prognostic Value ◽

Therapeutic Potential ◽

Small Cell Lung Carcinoma ◽

Lung Squamous Cell Carcinoma ◽

Small Cell ◽

The Cancer Genome Atlas ◽

Small Cell Lung ◽

Cell Lung Carcinoma ◽

Lung Cancers

AbstractScavenger receptor class F member 1 (SCARF1) has previously been shown to be highly expressed within the human liver, hold prognostic value in hepatocellular carcinoma and mediate the specific recruitment of leukocytes to liver sinusoidal endothelial cells; however, to date, the liver remains the only major organ in which SCARF1 has been explored in any detail. Here, we utilised publically-available RNA-sequencing data from The Cancer Genome Atlas (TGCA) to identify the lungs as a site of significant SCARF1 expression and attribute the majority of its expression to endothelial cell populations. Next, we show that SCARF1 expression is significantly reduced in two histologically distinct types of non-small cell lung carcinoma cancers (NSCLCs), lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC), compared to non-tumoural tissues. Interestingly, loss of SCARF1 expression was associated with aggressive tumour biology in LUAD tissues, but not in LUSC. Furthermore, increased SCARF1 expression was highly prognostic of better overall survival in LUAD tumour tissues, but this was again in contrast to LUSC tumours, in which SCARF1 held no prognostic value. Finally, we showed that SCARF1 is widely expressed in tumour endothelial cells of non-small cell lung cancers and that its total expression in LUAD tumour tissues correlated with immune score and CD4+ T cell infiltration. This study represents the first detailed exploration of SCARF1 expression in normal and diseased human lung tissues and further highlights the prognostic value and therapeutic potential of SCARF1 in immunologically active cancers.

Download Full-text

Prognostic Value and Therapeutic Potential of TREM-1 in Streptococcus pyogenes-Induced Sepsis

Journal of Innate Immunity ◽

10.1159/000348283 ◽

2013 ◽

Vol 5 (6) ◽

pp. 581-590 ◽

Cited By ~ 14

Author(s):

Sarah A. Horst ◽

Anna Linnér ◽

Andreas Beineke ◽

Sabine Lehne ◽

Claudia Höltje ◽

...

Keyword(s):

Streptococcus Pyogenes ◽

Prognostic Value ◽

Therapeutic Potential

Download Full-text

Sudden blindness with pituitary tumors

Journal of Neurosurgery ◽

10.3171/jns.1972.36.1.0083 ◽

1972 ◽

Vol 36 (1) ◽

pp. 83-85 ◽

Cited By ~ 21

Author(s):

Julian L. Robinson

Keyword(s):

Pituitary Tumor ◽

Prognostic Value ◽

Pituitary Tumors ◽

Pituitary Neoplasm ◽

Content Type ◽

Visual Improvement ◽

Sudden Blindness ◽

Fine Print

✓ Three patients in whom pituitary tumor led to sudden blindness are described; in two, there had been no other indication of a pituitary neoplasm. The authors believe that observation of these patients for 24 hours after the onset of blindness has prognostic value and is safe. If visual improvement occurs during this time, the chances of useful recovery of vision are good. Further delay is contraindicated since in spite of visual improvement, these patients may show a general deterioration which may terminate fatally unless operation is performed.

Download Full-text

HSP90 as a regulator of extracellular matrix dynamics

Biochemical Society Transactions ◽

10.1042/bst20210374 ◽

2021 ◽

Author(s):

Abir Chakraborty ◽

Adrienne Lesley Edkins

Keyword(s):

Extracellular Matrix ◽

Molecular Chaperone ◽

Prognostic Value ◽

Therapeutic Potential ◽

Tissue Homeostasis ◽

Protein Homeostasis ◽

Matrix Dynamics

The extracellular matrix (ECM) is a dynamic and organised extracellular network assembled from proteins and carbohydrates exported from the cell. The ECM is critical for multicellular life, providing spatial and temporal cellular cues to maintain tissue homeostasis. Consequently, ECM production must be carefully balanced with turnover to ensure homeostasis; ECM dysfunction culminates in disease. Hsp90 is a molecular chaperone central to protein homeostasis, including in the ECM. Intracellular and extracellular Hsp90 isoforms collaborate to regulate the levels and status of proteins in the ECM via multiple mechanisms. In so doing, Hsp90 regulates ECM dynamics, and changes in Hsp90 levels or activity support the development of ECM-related diseases, like cancer and fibrosis. Consequently, Hsp90 levels may have prognostic value, while inhibition of Hsp90 may have therapeutic potential in conditions characterised by ECM dysfunction.

Download Full-text